Delivery Order SPE2DR25D2106-SPE2DR26F1FZU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,817.44 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count) on December 4, 2025, with completion scheduled for December 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Atovaquone-Proguanil is an antimalarial medication commonly used for malaria prophylaxis and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,083.60 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100-count units) with an ultimate completion date of November 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Atovaquone-Proguanil is a combination antimalarial medication commonly used for malaria...
- The Defense Logistics Agency awarded a $24,468 delivery order to AmerisourceBergen Drug Corp on December 5, 2024, for the supply of Atovaquone-Proguanil 250-100 tablets in quantities of 100, with an ultimate completion date of December 6, 2024. This contract represents a firm fixed price, competitively awarded delivery order with no set-aside designation, performed at the contractor's facility in Conshohocken, Pennsylvania. Atovaquone-Proguanil is an antimalarial medication commonly used for...
- The Defense Logistics Agency awarded a delivery order valued at $1,117.35 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count) with an ultimate completion date of August 25, 2025. This firm fixed price, non-set-aside contract was awarded on August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The antimalarial medication will support federal medical supply requirements, likely for military personnel...
- The Defense Logistics Agency awarded a delivery order valued at $2,854.36 to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Atovaquone-Proguanil 250-100 mg tablets (100 count). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of November 7, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $38,258.58 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100mg tablets in a quantity of 100 units. This competitively awarded, firm fixed-price contract with no set-aside designation was issued on November 13, 2025, with an ultimate completion date of November 14, 2025. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania. Atovaquone-Proguanil is an...
- The Defense Logistics Agency awarded a delivery order valued at $34,433.39 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 tablets (100-count units) with an ultimate completion date of December 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The product is an antimalarial medication commonly used for malaria...
- The Defense Logistics Agency awarded a delivery order valued at $10,096.69 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 100 tablets, with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Atovaquone-Proguanil is an antimalarial medication commonly used for malaria prophylaxis and treatment in military...
- The Defense Logistics Agency awarded a delivery order valued at $5,905.94 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 mg tablets (100 count) on December 3, 2025, with an ultimate completion date of December 4, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The pharmaceutical product is an antimalarial medication...
- The Defense Logistics Agency awarded a delivery order valued at $29,337.37 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 mg in quantities of 100 tablets. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract was executed on December 2, 2025, with an ultimate completion date of December 3, 2025, and will be performed at the vendor's corporate office location in...
- SPE2DR25D2106Indefinite Delivery Contract
- SPE2DR25D2106-SPE2DR26F1FZUDelivery Order
The Defense Logistics Agency awarded a $2,637.27 delivery order to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count) on December 16, 2025, with completion targeted for December 17, 2025. This competitively awarded, firm fixed-price order was placed without a set-aside designation and will be fulfilled at the vendor's Conshohocken, Pennsylvania location. Atovaquone-Proguanil is a combination antimalarial medication commonly used for malaria prophylaxis and treatment, indicating this procurement supports military health readiness and force protection initiatives. This delivery order operates as a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen routinely fulfills diverse pharmaceutical and medical supply requirements across the Defense Health Agency and military healthcare systems worldwide. The firm's extensive portfolio with DLA demonstrates its established capability to deliver pharmaceutical products with consistency and reliability across multiple therapeutic categories supporting military operations and personnel health needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 12/15/25 |